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Background. The factors that contribute to increasing obesity rates in human immunodeﬁciency virus (HIV)-
positive persons and to body mass index (BMI) increase that typically occurs after starting antiretroviral therapy
(ART) are incompletely characterized.
Methods. We describe BMI trends in the entire Swiss HIV Cohort Study (SHCS) population and investigate the
effects of demographics, HIV-related factors, and ART on BMI change in participants with data available before and
4 years after ﬁrst starting ART.
Results. In the SHCS, overweight/obesity prevalence increased from 13% in 1990 (n = 1641) to 38% in 2012
(n = 8150). In the participants starting ART (n = 1601), mean BMI increase was 0.92 kg/m2 per year (95% conﬁdence
interval, .83–1.0) during year 0–1 and 0.31 kg/m2 per year (0.29–0.34) during years 1–4. In multivariable analyses,
annualized BMI change during year 0–1 was associated with older age (0.15 [0.06–0.24] kg/m2) and CD4 nadir <199
cells/µL compared to nadir >350 (P < .001). Annualized BMI change during years 1–4 was associated with CD4 nadir
<100 cells/µL compared to nadir >350 (P = .001) and black compared to white ethnicity (0.28 [0.16–0.37] kg/m2).
Individual ART combinations differed little in their contribution to BMI change.
Conclusions. Increasing obesity rates in the SHCS over time occurred at the same time as aging of the SHCS
population, demographic changes, earlier ART start, and increasingly widespread ART coverage. Body mass index
increase after ART start was typically biphasic, the BMI increase in year 0–1 being as large as the increase in years 1–4
combined. The effect of ART regimen on BMI change was limited.
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Obesity is a major long-term concern in human im-
munodeﬁciency virus (HIV)-positive (HIV+) persons
given their increased cardiovascular risk [1], and the
pathogenic link of obesity to diabetes mellitus, cardio-
vascular disease [2, 3], and all-cause mortality [4].
Soon after the introduction of antiretroviral treatment
(ART), regional body fat distribution abnormalities
became important metabolic concerns [5, 6]. With
the use of the thymidine-analogs zidovudine and sta-
vudine essentially disappearing in Western countries,
lipoatrophy [7] has been receiving less attention and
concern has shifted towards lipohypertrophy and obe-
sity. Obesity is now increasingly recognized as a prob-
lem in HIV+ persons, and it has been attributed to
improved health due to effective ART, normal aging,
and obesity trends similar to those seen in the general
population [8–17]. However, large-scale, longitudinal
analyses are not available.
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In this study, we describe obesity trends and concurrent de-
mographic changes from 1990 to 2012 in the nationally repre-
sentative Swiss HIV Cohort Study (SHCS), which currently
follows more than 8000 active patients [18]. We also investigate
the contribution of demographics, HIV-related factors, and the
most commonly used ART combinations to body mass index
(BMI) change after 1 and 4 years of ART in 1601 participants
who started a ﬁrst ART regimen after January 1, 1998. This
study represents the most comprehensive longitudinal BMI
analysis undertaken in HIV+ persons.
METHODS
Study Participants
Participants included HIV+ persons, aged ≥16 years who were
followed in the SHCS (www.shcs.ch) [18]. The study was ap-
proved by local ethics committees. All participants provided
written informed consent.
We present 2 main types of analyses: ﬁrst, a population-based
descriptive analysis of all SHCS patients with at least 1 available
BMI from 1990 to 2012 (Figure 1; Supplementary Figure 1; Sup-
plementary Table 1); second, detailed analyses of BMI changes
from 0–1 and 1–4 years after starting ART in participants ini-
tiating a ﬁrst ART regimen after January 1, 1998 (Tables 1 and 2;
Supplementary Tables 2 and 3; Supplementary Figure 2).
To limit confounding, pregnant females and patients with inci-
dent cancer or acquired immune deﬁciency syndrome (AIDS)-
deﬁning events after ART start were excluded. We also excluded
participants with missing CD4 (+120/−30 days at ART start) or
BMI information (+120/−120 days at ART start and at 1 and 4
years thereafter), those with ≥62 days of ART interruption,
and injection drug users (IDUs), due to low numbers, increased
rates of dropout, and missing data. A common reason for
missing BMI information was ART initiation before SHCS
enrollment.
Deﬁnitions and Measures
Body mass index (kg/m2) was stratiﬁed into <18.5 (under-
weight), 18.5–24.9 (normal), 25–29.9 (overweight), and 30
(obese), without modiﬁcation for Asians [19]. Hepatitis C coin-
fection was deﬁned as detectable hepatitis C virus (HCV) RNA.
Smoking was stratiﬁed into ever, never, and smoking cessation
during follow-up. xTC refers to ART containing either 3TC
(lamivudine) or FTC (emtricitabine).
Statistical Analysis
Categorical variables were compared with χ2 tests, and contin-
uous variables were assessed with non-parametric methods
(Kruskal-Wallis equality-of-populations rank test or tests for
trend over calendar year, whichever was applicable). We per-
formed bi- and multivariable linear regression analyses to inves-
tigate the effects of HIV transmission groups, age, CD4 nadir,
smoking, HCV coinfection, and ART agents on BMI after ART
initiation, presented as mean BMI changes (95% conﬁdence in-
tervals [CIs]). Antiretroviral agents are recorded with start and
stop dates in the SHCS, and ART exposure was assessed at every
follow-up visit.
Assumptions underlying these analyses were veriﬁed in scat-
ter diagrams. In exploratory analyses, BMI trajectories after
ART start were typically biphasic, with an initial rapid BMI
gain corresponding approximately to the ﬁrst year, and a small-
er BMI gain during years 1–4 of ART. Therefore, subsequent
detailed analyses were performed separately for years 0–1 and
1–4 of ART. Multivariable linear regression models for BMI
change during year 1 were adjusted for BMI at ART start,
HIV transmission group, age per 10 years, ethnicity (white,
black, Asian, other), CD4 nadir (0–99, 10–199, 200–349,
>350 cells/µL), smoking (never, ever, smoking cessation), and
ART regimen. During year 1–4 of ART, additional adjustments
were for BMI after 1 year of ART and pegylated interferon treat-
ment. Antiretroviral treatment exposure was considered in 3
ways: most frequent ART regimens (Table 2; Supplementary
Table 2), nucleoside reverse-transcriptase inhibitor (NRTI)
backbones (Supplementary Table 3), and third agents (Supple-
mentary Table 3), each deﬁned as being administered during
≥50% of the respective time periods (years 0–1 and 1–4). An-
tiretroviral treatment regimens with <50 person-years of expo-
sure were summarized in an “other” category.
Based on multivariable linear regression analyses, we made
standardized predictions of mean BMI changes [kg/m2 per
year] for different HIV transmission categories (men who have
sex with men [MSM], male heterosexual, female heterosexual),
for different ethnicities (white, black, Asian), and different age
groups (30–40, 41–50, 50+ years). For predictions, we ﬁxed the
remaining variables CD4 at 200–350 cells/µL, smoking status at
never smoking, and baseline BMI at 22 kg/m2. Interactions be-
tween BMI changes and ART, transmission groups, and ethnicity
were analyzed with a likelihood ratio test. We performed sensitiv-
ity analyses adjusting for calendar periods (2003–2005, 2006–
2008, and 2009 and after). All analyses were done using Stata
(version 13.1; StataCorp, College Station, TX).
RESULTS
Population BMI Trends, 1990–2012
The BMI distribution in the entire SHCS population stratiﬁed by
calendar year is shown in Figure 1 and Supplementary Figure 1,
respectively. From 1990 to 2012, the percentage of normal weight
and underweight participants decreased. Median BMI and the
percentage of obese and overweight participants increased (Fig-
ure 1; Supplementary Table 1). In 2012, the median BMI was 24
kg/m2 (interquartile range, 22–27), and 57% (95% CI, 56%–58%)
of the population were normal weight, 4.3% (3.9–4.7) were un-
derweight, 29% (28–30) were overweight, and 9.3% (8.6–9.9)
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were obese. From 1990 to 2012, the percentage of white part-
icipants (P < .001), IDUs (P < .001), and participants with
AIDS-deﬁning illnesses decreased (P < .001). The percentage of
women (P = .03), participants on ART (P < .001), the median
CD4 cell count at ART initiation (P < .001), and the median
age of participants increased (P < .001).
Fig. 1. Longitudinal trends of population body mass index (BMI) categories and median BMI trajectory, entire Swiss HIV Cohort Study population, 1990–
2012. Note: Conﬁdence intervals are omitted for visual clarity. Abbreviations: AIDS, acquired immune deﬁciency syndrome; IDU, injection drug user; ART,
antiretroviral therapy.
Table 1. Baseline Characteristics of 1601 SHCS Participants Who Started a First ART Regimen After January 1, 1998
All MSM* Heterosexual male Heterosexual female P-value*
Participants, n (%) 1601 (100) 892 (56) 390 (24) 319 (10)
Age, median years (IQR) 40 (34–47) 40 (34–45) 44 (36–53) 37 (32–45) <0.001
Ethnicity
White, n (%) 1280 (80) 808 (91) 315 (81) 157 (49) <0.001
Black, n (%) 181 (11) 10 (1) 65 (17) 106 (33)
Asian, n (%) 83 (5) 38 (4) 4 (1) 41 (13)
Other, n (%) 57 (4) 36 (4) 6 (2) 15 (5)
Smoking ever, n (%) 613 (38) 377 (42) 149 (38) 87 (27) <0.001
HCV coinfection, n (%) 21 (1) 7 (1) 9 (2) 5 (2) 0.08
CD4 nadir, cells/µL, median (IQR) 217 (131–289) 235 (161–305) 199 (103–271) 194 (93–265) <0.001
HIV-RNA at start of ART, log10 copies/mL 4.8 (4.2–5.4) 4.9 (4.3–5.3) 4.9 (4.2–5.5) 4.7 (4.0–5.3) 0.04
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sexwith men; SD; standard deviation;
SHCS, Swiss HIV Cohort Study.
* MSM are compared with heterosexual males and females.
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Table 2. Bi- and Multivariable Linear Regression of BMI Changes During Year 0–1 and Years 1–4 of ART Among 1601 SHCS Participants
Who Started a First ART Regimen After January 1, 1998
Covariables
Year 0-1 of ART Years 1–4 of ART
Coefficient Bivariable
models (95% CI)a
P
Value
Coefficient
Multivariable Models
(95% CI)b
P
Value
Coefficient Bivariable
Models (95% CI)c
P
Value
Coefficient
Multivariable Models
(95% CI)b
P
Value
Baseline
BMId
−0.09 (−.11 to .07) <.001 −0.09 (−.11 to −.06) <.001 −0.02 (−.03 to −0.01) <.001 −0.01 (−.02 to −.00) .002
Delta BMI
change,
first year of
ART
– – – – −0.05 (−.07 to −.03) <.001 −0.06 (−.07 to −.04) <.001
HIV transmission group
MSM 1 – 1 – 1 – 1 –
Het male 0.46 (.24 to .68) <.001 0.20 (−.02 to .42) .07 0.06 (−.02 to 0.13) .14 0.02 (−.05 to .10) .53
Het female 0.18 (−.06 to .41) .14 0.07 (−.18 to .32) .58 0.05 (−.03 to .13) .24 −0.03 (−.11 to .06) .52
Age per 10
yearse
0.25 (.16 to .34) <.001 0.15 (.06 to .24) .002 0.01 (−.02 to .04) .35 0.02 (−.01 to .05) .14
Ethnicity
White 1 – 1 – 1 – 1 –
Black 0.04 (−.25 to .33) .80 −0.05 (−.36 to .26) .74 0.26 (.16 to .35) <.001 0.28 (.16 to .37) <.001
Asian −0.60 (−1.0 to −.18) .005 −0.79 (−1.2 to −.39) <.001 −0.01 (−.15 to .13) .87 0.01 (−.13 to .15) .88
Other −0.44 (−.93 to .05) .08 −0.25 (−.71 to .21) .29 −0.01 (−.17 to .15) .90 −0.03 (−.19 to .13) .71
CD4 nadir
0–99 cells/
µL
1.73 (1.45 to 2.02) <.001 1.64 (1.4 to 1.9) <.001 0.40 (.14 to .66) .002 0.44 (.19 to .70) .001
100–199
cells/µL
0.50 (.24 to .76) <.001 0.46 (.19 to .72) .001 −0.04 (−.16 to .07) .44 0.05 (−.07 to .17) .40
200–349
cells/µL
−0.00 (−.21 to .21) .99 −0.02 (−.23 to .19) .82 0.04 (−.03 to .11) .28 0.07 (−.00 to .14) .05
≥350 cells/
µL
1 – 1 – 1 – 1 –
Smoking,
ever
−0.46 (−.65 to −.27) <.001 −0.29 (−.47 to −.11) .002 −0.04 (−.10 to .02) .20 – –
Smoking
cessation
−0.11 (−.78 to .56) .75 – – 0.15 (.03 to .26) .01 0.16 (.04 to .27) .006
HCV
coinfection
−0.73 (−1.5 to .06) .07 – – −0.26 (−.46 to −0.06) .01 – –
Peginf 0.56 (−3.1 to 4.2) .76 – – −0.72 (−1.1 to −.37) <.001 –0.71 (−1.0 to −.37) <.001
Most frequent ART regimens
TDF, xTC,
EFV
1 − 1 − 1 − 1 −
ABC, xTC,
EFV
0.27 (−.20 to .75) .26 0.21 (−.23 to .64) .35 −0.01 (−.16 to .15) .95 −0.01 (−.16 to .14) .89
ABC, xTC,
LPV
0.51 (−0.05 to 1.1) .08 0.22 (−.30 to .74) .41 0.14 (−.07 to .35) .21 0.15 (−.06 to .36) .16
ABC, xTC,
ATV,
RTV
0.15 (−0.50 to .80) .66 0.19 (−.41 to .79) .53 0.16 (−.04 to .36) .11 0.14 (−.05 to .33) .16
AZT, xTC,
EFV
0.04 (−.30 to .39) .81 −0.13 (−.45 to .20) .44 −0.16 (−.28 to −.04) .01 −0.17 (−.29 to −.05) .006
AZT, xTC,
LPV
0.54 (.19 to .89) .003 0.29 (−.04 to .62) .08 −0.16 (−.30 to −.02) .03 −0.12 (−.25 to .02) .09
AZT, xTC,
NFV
0.27 (−.27 to .80) .33 −0.09 (−.59 to .41) .73 −0.25 (−.46 to −.03) .02 −0.22 (−.43 to −.01) .04
TDF, xTC,
LPV
0.45 (.10 to .80) .01 0.30 (−.03 to .62) .08 0.08 (−.07 to .23) .30 0.06 (−.08 to .21) .38
TDF, xTC,
NVP
−0.09 (−.60 to .42) .73 0.06 (−.42 to .54) .81 0.00 (−.14 to .14) .97 0.03 (−.10 to .16) .65
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BMI Change After ART Initiation
From January 1, 1998 to December 31, 2012, 5415 SHCS par-
ticipants with MSM or heterosexual HIV transmission started a
ﬁrst ART regimen. Stringent inclusion criteria resulted in a sub-
stantial reduction of participants (Supplementary Figure 2).
Subsequent analyses are based on 1601 participants (Table 1;
Supplementary Table 2), 6250 person-years of follow-up, and
4803 BMI measurements. Median age at ART start was 40
years, 80% were white, and 19% were female. Body mass
index change after ART initiation was biphasic; the mean
BMI change during year 0–1 of ART was 0.92 kg/m2 per year
(95% CI, .83–1.0), and during years 1–4 was 0.31 (0.29–0.34)
kg/m2 per year. The mean interval between BMI determinations
was 0.99 years (range, 0.43–1.5 years) between baseline and year
1 after ART start, and 2.9 years (1.7–4.2) between years 1 and 4.
Body Mass Index Change, Year 0–1 After ART Start
In the ﬁnal, multivariable adjusted model, there was a trend to-
wards larger BMI gain in heterosexual males compared with
MSM. Compared with whites, annualized BMI change was
not different in black and other ethnicities, but smaller in
Asians (−0.79 [95% CI, −1.2 to −.39] kg/m2; P = .001). Body
mass index change was associated with older age (0.15 [0.06–
0.24] kg/m2 per 10 years older; P = .002). Compared to CD4
nadir >350 cells/µL, a CD4 nadir of 0–99 and 100–199 cells/
µL had the largest effect on BMI change (1.64 [1.4–1.9] kg/m2
per year; P < .001 and 0.46 [0.19–0.71] kg/m2 per year; P = .001,
respectively). Smoking was associated with a BMI decrease
(−0.29 [−0.47 to 0.11] kg/m2 per year; P = .002). Body mass
index change was similar with the ten most commonly pre-
scribed ART regimens. Body mass index change was also sim-
ilar for different NRTI backbones and third drugs, except for
raltegravir, which was associated with a BMI change of 1.0
([0.17–1.8] kg/m2 per year; P = .018), compared with efavirenz
(Supplementary Table 3). These multivariable associations re-
mained unchanged after adjustment for calendar period. No
signiﬁcant interactions were detected between BMI changes
and ART, transmission groups, and ethnicity.
Body Mass Index Changes, Years 1–4 After ART Start
In the ﬁnal, multivariable adjusted model, BMI change was sim-
ilar in heterosexual males (0.02 [95% CI, −.05 to 0.10] kg/m2
per year; P = .53) and females (−0.03 [−0.11 to 0.06] kg/m2
per year; P = .52) compared with MSM. No age effect on BMI
change was identiﬁed during years 1–4 (0.02 [−0.01 to 0.05] kg/
m2 per year; P = .14). Body mass index gain was larger in black
compared with white participants (0.28 [0.16–0.37] kg/m2 per
year; P < .001). Body mass index change was also associated
with CD4 nadir 0–99 cells/µL (0.44 [0.19–0.70] kg/m2 per
year; P = .001) compared to CD4 nadir >350 cells/µL, with
smoking cessation (0.16 [0.04–0.27] kg/m2 per year; P = .006)
and with pegylated interferon (−0.71 [−1.0 to −0.37] kg/m2
per year; P < .001). Compared to calendar period 1998–2002,
BMI change was similar in 2003–2005 (P = .57), but it increased
in 2006–2008 (0.12 [0.03–0.21] kg/m2; P = .008) and in 2009
and after (0.19 [0.09–0.28] kg/m2 per year; P < .001). No signif-
icant interactions were detected between BMI changes and
ART, transmission groups, and ethnicity. Body mass index
change was similar for the 10 most commonly prescribed
ART regimens (Table 2). As regards NRTIs and third agents
(Supplementary Table 3), compared with tenofovir/xTC and
efavirenz, zidovudine was associated with a smaller BMI in-
crease, in combination with either efavirenz/xTC (−0.17
[−0.29 to −0.05] kg/m2 per year; P = .006) or with nelﬁnavir/
Table 2 continued.
Covariables
Year 0-1 of ART Years 1–4 of ART
Coefficient Bivariable
models (95% CI)a
P
Value
Coefficient
Multivariable Models
(95% CI)b
P
Value
Coefficient Bivariable
Models (95% CI)c
P
Value
Coefficient
Multivariable Models
(95% CI)b
P
Value
TDF, xTC,
ATV,
RTV
0.04 (−.30 to .39) .80 0.12 (−.20 to .44) .45 0.01 (−.11 to .13) .89 0.06 (−.05 to .17) .30
Otherf 0.27 (−.01 to .55) .06 0.14 (−.12 to .40) .29 −0.06 (−.14 to .03) .17 −0.04 (−.12 to .04) .36
Abbreviations: ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir; AZT, zidovudine; BMI, body mass index; CI, confidence interval; EFV, efavirenz; HCV,
hepatitis C virus; Het, heterosexual; LPV, lopinavir; NFV, nelfinavir; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; Other, patients with no
backbone or no third drug for 50% of the time or patients with 3 class regimens; Peginf, pegylated interferon; RAL, raltegravir; RTV, ritonavir; SHCS, Swiss HIV
Cohort Study; TDF, tenofovir; xTC, lamivudine or emtricitabine.
a All covariables of the bivariable model were adjusted for baseline BMI.
b Multivariable models were adjusted for all variables listed.
c All covariables of the bivariable model were adjusted for BMI after 1 year of ART.
d Baseline BMI at start of ART and BMI after 1 year of ART, respectively.
e Age at baseline (January 1, 1998 or at registration in the SHCS, whichever is the later) and after 1 year of ART.
f Contains all ART regimens with <50 person-years of exposure.
BMI Changes Among HIV-Positive Persons • OFID • 5
xTC (−0.22 [−0.43 to −0.01] kg/m2 per year; P = .04). The
NRTI backbones zidovudine/abacavir/xTC, zidovudine/xTC,
and d4T/xTC were associated with a BMI decrease when com-
paring them with tenofovir/xTC (−0.20 [−0.32 to −0.08], 0−.20
[−0.28 to −0.13], and −0.35 [−0.67 to −0.04] kg/m2 per year,
respectively). There was a larger BMI increase with atazanavir/
ritonavir compared with efavirenz (P = .03) (Supplementary
Table 3).
The effects of transmission category, ethnicity, and age
groups are further illustrated in Figure 2, which shows predicted
BMI changes during years 0–1 and 1–4 of ART. The BMI in-
crease was biphasic in white patients and black women, and
the age effect was restricted to year 0–1 of ART.
DISCUSSION
This study has 3 major ﬁndings; ﬁrst, obesity rates in the SHCS
have been increasing since 1995 in the setting of demographic
changes, earlier ART start, and more widespread population
ART coverage; second, BMI increase after ART initiation typi-
cally was biphasic, and the BMI increase in year 0–1 was as large
as the increase in years 1–4 combined and was related most no-
tably to the CD4 nadir; and third, we found little evidence that
the individual ART regimen selected is a major driver of the ex-
tent of BMI change after ART start.
We describe a number of changes in demographics and in
HIV management that may be partially responsible for the in-
creasing obesity prevalence in the entire SHCS population over
time, including an aging population, fewer IDU, initiation of
ART at higher CD4 counts, and increasingly complete ART
coverage. Injection drug use has been associated with lower
BMI, more weight loss, and less weight gain after ART start,
compared with other HIV+ persons [20], but not in all studies
[11]. Before ART start, BMI typically declines with advanced
HIV infection [21] and may predict survival and progression
to AIDS [22]. In contrast, earlier ART start in recent years
may prevent opportunistic complications, wasting, and the as-
sociated weight loss. Successful ART has produced an aging
HIV+ population that is in much better health [23]. Advancing
age is an important contributor to BMI in the general popula-
tion [14, 15, 17, 24–26]. Increasing obesity rates have previously
been recorded in HIV+ populations [11, 13, 23, 27], and the per-
centages of normal weight, underweight and overweight per-
sons in the SHCS in 2012 was very similar to the percentages
reported in the Swiss general population in 2012 [28].
Our study represents the most comprehensive assessment of
longitudinal BMI change after ART start to date. In detailed
analyses, we found BMI change after ART initiation to be a bi-
phasic process that included a mean increase during the ﬁrst
year of ART that was as large as the mean increase during the
3 subsequent years combined. A biphasic BMI behavior has not
previously been described; it likely represents a rapid re-gain of
weight lost during untreated HIV infection [6, 10], perhaps sim-
ilar to the return of plasma lipid levels to preinfection levels
after ART start [29]. The biphasic BMI increase resembles the
biphasic CD4+ lymphocyte increase after starting ART, which is
initially rapid and followed by a second phase of slower CD4
increase [30]. We observed a biphasic BMI increase after ART
start in white participants and in black women; there were lim-
ited numbers of patients of other ethnicities in our study and
CIs were wide.
The largest contributor to BMI increase was the CD4 nadir. A
larger degree of weight loss before ART that may occur with
profound immunosuppression presumably correlates with a
larger degree of weight re-gain after ART start. The BMI effect
of a CD4 nadir < 100 cells/µL persisted into years 1–4 of ART.
An effect of the CD4 nadir on weight gain during the ﬁrst [31]
and the ﬁrst 2 years [20] of ART has been previously reported.
Contrary to our expectations, smoking and advancing age had
no effect on BMI behavior during years 1–4 of ART, whereas
smoking cessation was associated with larger BMI gain, consis-
tent with data from the general population [32].
We found a limited contribution of the selected ART regimen
to BMI change. Potential differences between individual drugs
were not apparent when the BMI effect of commonly used ART
combinations was examined during prolonged exposure (years
1–4). Our ﬁndings extend previous reports including a random-
ized study (422 participants; median follow-up, 5 years) in
which median BMI increase did not differ with protease inhib-
itor (PI) vs non-NRTI (NNRTI) treatment, even though indi-
vidual PIs and NNRTIs were not compared [33]. In AIDS
Clinical Trials Group (ACTG) Study A5142 (753 participants),
the median BMI increase did not differ between treatment arms
at 96 weeks [34]. A5142 compared lopinavir/ritonavir vs efavir-
enz vs both, and stavudine vs tenofovir vs zidovudine. In ACTG
A5224s, a larger mean BMI gain was noted at 96 weeks in pa-
tients randomized to atazanavir/ritonavir (n = 109) compared
with efavirenz (n = 94) [35]. In an observational study of 681 pa-
tients, PI treatment was associated with greater weight gain than
NNRTI treatment after 2 years of ART, but individual PIs and
NNRTIs were not assessed [20].
Zidovudine-containing regimens were associated with small-
er BMI increases in the SHCS compared with other regimens.
This result is consistent with the well recorded, sustained effect
of thymidine analogs on peripheral fat loss [7, 36, 37] and sug-
gests that lipoatrophy may result in an attenuated BMI gain, as
previously reported [10]. The increased BMI gain in our study
in more recent calendar periods may partially be related to little
use of thymidine analogs [9].We note that 2 studies conducted
during 1999–2002 and 1999–2003, respectively, reported no
longitudinal BMI increase in HIV+ persons [38, 39]. Possible
explanations for this include much less widespread ART use
during the early ART era and, if ART was given, it typically in-
cluded thymidine analogs.
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Fig. 2. Adjusted predicted annualized body mass index (BMI) changes during years 0–1 and years 1–4 of ART start. Separate predictions of BMI changes/
year are presented for human immunodeﬁciency virus transmission category, gender, ethnicity, and age groups. Results are based on multivariable regres-
sion models adjusted for transmission category, ethnicity, age group, CD4 categories, and smoking status. For predictions, we ﬁxed the remaining variables
CD4 at 200–350, never smoking, and baseline BMI of 22 kg/m2. Abbreviations: hetero, heterosexual; MSM, men who have sex with men.
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Strengths of this study include longitudinal data collection in
an established, large observational study. Due to the prospective
design of the SHCS, we were able to control for important co-
factors. Limitations include that information on diet and certain
psychiatric comedications potentially associated with weight
gain are not yet systematically captured; alcohol use and phys-
ical activity has been recorded since 2009 and was not consid-
ered in the present study. Moreover, the SHCS does not collect
information on poverty, an important social determinant of
BMI change.
In conclusion, increasing obesity rates in the SHCS popula-
tion have occurred at the same time as trends towards restora-
tion of health and normal aging in the setting of increasingly
widespread population ART coverage. Ethnicity and immune
suppression (CD4 nadir) had important effects on BMI behav-
ior after ART start, but there was no clear evidence that fre-
quently used ART regimens differ in their inﬂuence on BMI
change during 4 years of follow-up. Similar to the general pop-
ulation, HIV+ patients should be motivated to consider a
healthy lifestyle including diet, exercise, and behavioral
modiﬁcations.
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